Pfizer

Companies Pfizer

News Pfizer

• Pfizer contemplates $2 billion acquisition of Strides’ Agila Unit

  As drug makers continue to jostle for market share and deal with declining revenues from their off-patent blockbuster drugs, M&A activity is showing no indication of slowing down in 2013. Pfizer is not leaving any stone unturned as the company continues its growth. Less than two months after complet more

• SFJ Pharmaceuticals and Pfizer to co-develop dacomitinib as treatment for non-small cell lung cancer

  The SFJ Pharmaceuticals Group (SFJ), announced that it has entered into a collaborative development agreement with Pfizer Inc. to conduct a Phase 3 clinical trial of Pfizer’s investigational pan-HER (pan-human epidermal growth factor receptor) inhibitor, dacomitinib (PF-00299804).  The trial, which more

• Karo Bio Enters Collaboration with Pfizer to Discover and Develop Innovative Drugs for Autoimmune Diseases

  Karo Bio AB has entered into a research collaboration agreement with Pfizer Inc., to discover and develop novel small molecule RORgamma modulators for the treatment of autoimmune diseases.Under the agreement, Pfizer will provide full funding for the research costs and have the exclusive right to mar more

White papers Pfizer

• Orphan Drugs – An Alternative to the declining Blockbuster Model?
  

  Up until the new millennium, the pharmaceutical industry grew stronger by 11%. However, the blockbuster model is increasingly at risk and the declining growth rates in the industry require a search for new strategies. In this context, orphan drugs are becoming increasingly important more

Publications Pfizer

• Mitoxantrone Targets the ATP-binding Site of FAK, Binds the FAK Kinase Domain and Decreases FAK, Pyk-2, c-Src, and IGF-1R In Vitro Kinase Activities

  Abstract: Focal Adhesion Kinase (FAK) is a non-receptor kinase that is overexpressed in many types of tumors and plays a key role in cell adhesion, spreading, motility, proliferation, invasion, angiogenesis, and survival. Recently, FAK has been proposed as a target for cancer therapy, and we more

• Differences in Reporting of Analyses in Internal Company Documents Versus Published Trial Reports: Comparisons in Industry-Sponsored Trials in Off-Label Uses of Gabapentin

  by S. Swaroop Vedula, Tianjing Li, Kay Dickersin Background Details about the type of analysis (e.g., intent to treat [ITT]) and definitions (i.e., criteria for including participants in the analysis) are necessary for interpreting a clinical trial's findings. Our objective was to compare the des more

• Differences in Reporting of Analyses in Internal Company Documents Versus Published Trial Reports: Comparisons in Industry-Sponsored Trials in Off-Label Uses of Gabapentin

  by S. Swaroop Vedula, Tianjing Li, Kay Dickersin Background Details about the type of analysis (e.g., intent to treat [ITT]) and definitions (i.e., criteria for including participants in the analysis) are necessary for interpreting a clinical trial's findings. Our objective was to compare the des more

Market studies Pfizer

• China Pharmaceuticals and Healthcare Report Q2 2012

  BMI View: 2012 is a very important year for the country as the government look to carry on their achievements following the healthcare reform in 2009. We highlight that the expansion of the National Essential Drug List (NEDL) slated to happen this year will bring strong opportunities for pharmaceuti more

• Puerto Rico Pharmaceuticals and Healthcare Report Q2 2012

  BMI View: Puerto Rico is struggling to retain its reputation as a pharmaceutical manufacturing hub, with a number of plants found to be in breach of regulations and standards over recent years. Additionally, the flagging economy is expected to push skilled staff to emigrate, leaving fewer candidates more

• Osteopenia Therapeutics - Pipeline Assessment and Market Forecasts to 2019

  Introduction GlobalData, the industry analysis specialist, has released its new report, “Osteopenia Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Osteopenia Therapeutics market. The report identifies the more

Websites Pfizer